Real-world study of PD-1/L1 immune checkpoint inhibitors for advanced non-small cell lung cancer after resistance to EGFR-TKIs

Background Programmed cell death-1 (PD-1) and its ligand 1 (PD-L1) inhibitors have achieved good efficacy safety in patients with advanced EGFR mutation-negative non-small lung cancer (NSCLC), but their previous mutations is limited. The aim of the present study was to explore PD-1/L1 immune checkpoint for treatment NSCLC who are resistant EGFR-TKIs Methods This retrospective included 123 stage IV received Shanghai Changzheng Hospital between January 2019 2022 after failure first-line EGFR-TKIs. Of them, 39 ICIs + chemotherapy anti-angiogenic drugs (ICIs+BCP group), 51 monotherapy (ICIs 33 (BCP group). gender, age, smoking history, ECOG score, mutation type, PD-L1 TPS expression, first routine blood index before second-line all enrolled were recorded, clinical outcomes prognosis factors analyzed. Results There no significant difference objective response rate (ORR) disease control (DCR) three groups. Patients ICIs+BCP group had better than those (PFS:9.5 vs. 4.64 months, p<0.001; OS: 16.97 7.9 months p<0.001) or BCP (9.5 6.48 p<0.005; 11.39 p<0.005). Conclusion Our findings suggest that real-world practice China, combined effective